 |
 Video: What is a Stock Split?
|
|
|
| Aligos Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of non-alcoholic steatohepatitis (NASH), coronavirus (e.g., Severe Acute Respiratory Syndrome coronavirus 2 and related infections) and chronic hepatitis B. Co.'s primary area of focus is NASH, a chronic liver disease. Co.'s primary drug candidate for NASH is ALG-055009, a small molecule thyroid hormone receptor agonist. This drug candidate is being evaluated in a Phase 1 study in healthy volunteers (oral single ascending doses and subjects with hyperlipidemia (14 oral daily doses). According to our Aligos Therapeutics stock split history records, Aligos Therapeutics has had 0 splits. | |
|
Aligos Therapeutics (ALGS) has 0 splits in our Aligos Therapeutics stock split history database.
Looking at the Aligos Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aligos Therapeutics shares, starting with a $10,000 purchase of ALGS, presented on a split-history-adjusted basis factoring in the complete Aligos Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/19/2020 |
|
| End date: |
05/01/2024 |
|
| Start price/share: |
$14.76 |
|
| End price/share: |
$0.77 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-94.78% |
|
| Average Annual Total Return: |
-56.64% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$521.66 |
|
| Years: |
3.53 |
|
|
|
|
|
